"Lilly's GLP-1 franchise is generating revenue growth that almost no large-cap company has ever sustained at this scale, with a full-year 2025 revenue of $65.18 billion, up 44.7% year-over-year."
"JPMorgan's full-year 2025 net income was $57.05 billion, down 2.43% year-over-year, with forward EPS growth at −3.6%, indicating a structural difference in growth compared to Lilly."
"80% of analysts covering Lilly are bullish, with a consensus price target of $1,209.21, while JPMorgan has only 52% bullishness and a target of $337.75."
Eli Lilly and JPMorgan Chase are both nearing $1 trillion market caps, with Lilly currently at $829 billion and JPMorgan at $798 billion. Lilly's GLP-1 franchise is driving unprecedented revenue growth, with a projected 2026 revenue of $80 billion to $83 billion. In contrast, JPMorgan's growth is declining, with a net income drop of 2.43% year-over-year. Analyst sentiment favors Lilly, with 80% bullishness and a price target suggesting a market cap above $1 trillion, while JPMorgan has only 52% bullishness.
Read at 24/7 Wall St.
Unable to calculate read time
Collection
[
|
...
]